Company news

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A (SSE:603168) news

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 22, 2026: "Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement…

Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A (SSE:603168) news

Press releases & updates

"Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Remaining Restricted Shares under the 2023 Stock Option and Restricted Share Incentive Plan

"Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement on Completion of Raised Funds Investment Projects

"Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement on Resolutions of the 16th Meeting of the 6th Board of Directors

"Zhejiang Shapuaisi Pharmaceutical Co., Ltd."Announcement on Obtaining the "Drug Registration Certificate" for Vitamin B12 Eye Drops

Announcement on Release of Pledge of Shares by Actual Controller

Announcement on Obtaining Drug Registration Certificate for Sildenafil Citrate Orally Disintegrating Tablets

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Proposed Termination of Acquisition of 100% Equity in Shanghai Qinli Industrial Co., Ltd. and Related Party Transactions

Report for Q1 2026

Indicative Announcement on Convening the 2025 Annual General Meeting

Announcement on Postponing Reply to Letter of Inquiry from SSE

Announcement on the Remuneration Plan for Directors and Senior Management Members in 2026

Announcement on Receipt of the "Letter of Shareholder Suggestions" from the China Securities Investor Services Center

Announcement on Receiving Letter of Supervision and Inquiry Regarding Related-Party Asset Purchase of Zhejiang Shapuaisi Pharmaceutical Co., Ltd. from Shanghai Stock Exchange

Announcement on Expected Loss in Performance for 2025

for Diflunisal Tablets

Indicative Announcement on Expected Loss in Performance for 2025

Announcement on Result of Shareholding Reduction by Shareholder through Call Auction

Announcement on Result of Shareholding Reduction by Shareholder

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trial of Phenylephrine and Ketorolac Solution

Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Circulation of Restricted Shares Issued to Specific Objects

Announcement on Obtaining Notice of Approval for Drug Supplementary Application

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase Ⅲ Clinical Trial of Litasert Eye Drops

Announcement on the Implementation of Repurchase and Cancellation of Some Restricted Stocks in the 2023 Stock Option and Restricted Stock Incentive Plan

Announcement on Shareholding Reduction Plan for Shareholders

Announcement on Postponement of Investment Projects Financed by Raised Funds

Announcement on Resignation of Director and Election of Employee Representative Director

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025

Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials for Pilocarpine HCI Ophthalmic Solution

Announcement on Obtaining the "Drug Registration Certificate" for Terbutaline Sulphate Solution for Nebulization

2025 Semi-annual Report

Announcement on Turnaround to Profitability for the 1st Half of 2025

Announcement on Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual Report

Announcement on the Result of Shareholding Reduction by Shareholder through Call Auction

Announcement on Release and Pledge of Controlling Shareholder's Shares

Announcement on the Pledge of Shares Held by the Controlling Shareholder

Indicative Announcement on Change in Equity of Shareholder with Over 5% Shares Reaching 1%

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Progress in Sale of Equity of Wholly-owned Sub-subsidiary

Announcement on Obtaining the "Notice of Approval for Drug Supplement Application" for Levofloxacin Eye Drops

Announcement on the Remuneration Plan for Directors, Supervisors and Senior Management Members in 2025

Announcement on Resolution of the 7th Meeting of the 6th Board of Supervisors

Announcement on Obtaining the Drug Registration Certificate for Polyvinyl Alcohol Eye Drops